Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome;Blødningskomplikationer ved behandling med clopidogrel og acetylsalicylsyre efter akut koronart syndrom

Ugeskrift for Laeger

Volumn 168, Issue 38, 2006, Pages 3209-3214

  Kjær, Janus ^a   Larsen, Christian Hastrup ^a   Poulsen, Tina Svenstrup ^a   Møller, Jacob E ^a   Mickley, Hans ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DEATH; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANGINA, UNSTABLE; ASPIRIN; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOLYTIC THERAPY; TICLOPIDINE;

EID: 33749241281     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 2001;345:494-502.
2. Fragmin and fast revascularisation during instability in coronary artery disease (FRISC II) investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:701-707
3. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Comittee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-969.
4. CURE study investigators. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopydidines in vascular disease. Eur Heart J 2000; 21:2033-2041.
5. Fox KAA, Mehta, SR, Peters R, et al. Benefits and Risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome. Circulation 2004; 110: 1202-1208.
6. Ascione R, Ghosh A, Rogers CA, et al. In-hospital patients exposed to clopidogrel before coronary artery bypass surgery: A word of caution. Ann Thorac Surg 2005; 79:1120-1126.
7. Chu MWA, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004; 78:1536-1541.
8. Therkelsen CJ, Lassen JF, Nørgaard BJ, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction:observations from an unselected cohort. Eur Heart J 2005;26, 18-26.
9. Buresly K, Eisenberg MJ, Zhang X, et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005;165:784-789.
10. Grande P, Holmvang L. Akut koronart syndrom. Retningslinier for diagnostik og behandling. Tillæg til Cardiologisk Forum, januar 2005.
11. ACC/AHA 2004 guidelines update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Eagle KA, Guyton RA. Davidoff R, Edwards FH, Ewy GA et al. Circulation 2004;110: 1168-1176.